Webinar: Prospects for Obesity Medicines
If you missed the live webinar, you can catch the recording on:
This event is taking place virtually, over Zoom. Click here to read the Zoom user guidance notes.
The recent launches of two highly effective obesity medicines – Wegovy & Mounjaro - have been hugely commercially successful & culturally influential. Despite these deserved accolades, this presentation will argue these two medicines are likely to have a negligible impact on population mortality.
The presentation will also argue a future wave of potential new obesity medicines could collectively overcome the drawbacks of Wegovy & Mounjaro. In turn, this future wave could create the potential for a positive impact on future population mortality.
Ivor has invested in over 700 listed biotech companies. As a result, Ivor has significant practical experience in assessing the effectiveness and commercial prospects of potential new medicines. He has had a long prior career in the life assurance & health insurance industries. Ivor is a member of the Society’s Healthcare Committee.